Skip to content

Deal · Funding3 October 2023 · Closed

Iambic Therapeutics raises $100 million Series B

The round is led by Ascenta Capital and Abingworth, with NVIDIA, Illumina Ventures and 9 others participating.

Iambic Therapeutics Issuer · Ascenta Capital Lead investor · Abingworth Lead investor · NVIDIA Investor · Illumina Ventures Investor · Gradiant Corporation Investor · Shanda Investor · Nexus Venture Partners Investor · Catalio Capital Management Investor · Coatue Investor · FreeFlow Investor · OrbiMed Investor · Sequoia Capital Investor · Tao Capital Investor

The deal

Type
Funding
Amount
$100M
Status
Closed
Round
Series B
Post-money
Not recorded
Region
United States
Date
3 October 2023

As of this development: a later development may record new terms.

Lifecycle

  1. AnnouncedNot recorded
  2. Closed3 October 2023 · This development

Investors in this round

Ascenta Capital · Lead investor

First round with Iambic Therapeutics

Abingworth · Lead investor

First round with Iambic Therapeutics

NVIDIA · Investor

First round with Iambic Therapeutics

Illumina Ventures · Investor

First round with Iambic Therapeutics

Gradiant Corporation · Investor

First round with Iambic Therapeutics

Shanda · Investor

First round with Iambic Therapeutics

Nexus Venture Partners · Investor

First round with Iambic Therapeutics

Catalio Capital Management · Investor

First round with Iambic Therapeutics

Coatue · Investor

First round with Iambic Therapeutics

FreeFlow · Investor

First round with Iambic Therapeutics

OrbiMed · Investor

First round with Iambic Therapeutics

Sequoia Capital · Investor

First round with Iambic Therapeutics

Tao Capital · Investor

First round with Iambic Therapeutics

Iambic Therapeutics’s rounds

3 rounds since 2023 · as disclosed: $250M

Iambic Therapeutics's funding rounds Minutes has recorded
DateRoundAmountPost-moneyLed byReturning
10 November 2025Funding roundat least $100M——6 of 16
18 June 2024Series B extension$50M—Mubadala Capital, Exor Ventures4 of 8
3 October 2023Series B · this round$100M—Ascenta Capital, Abingworth0 of 13

Ownership and exit

Listed

14 October 2026 · IPO · Closed · after 3 rounds since 2023 · The deal

Minutes shows stakes only when a party discloses them.

The parties

Iambic Therapeutics Issuer

4 developments · 4 deals in Minutes

Ascenta Capital Lead investor

1 development · 1 deal in Minutes

Abingworth Lead investor

3 developments · 3 deals in Minutes

NVIDIA Investor

20 developments · 16 deals in Minutes

More in Healthcare

Past 3 months in Activity →